Reno-cerebrovascular disease: Linking the nephron and neuron

Expert Review of Neurotherapeutics

Volumn 11, Issue 2, 2011, Pages 241-249

  Lee, Meng ^a,b,c   Ovbiagele, Bruce ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Albuminuria; Chronic kidney disease; CKD; Creatinine clearance; Cystatin C; Glomerular filtration rate; Incidence; Microalbuminuria; Outcomes; Prevalence; Prognosis; Proteinuria; Renal function; Stroke; Urinary albumin excretion

Indexed keywords

CYSTATIN C;

ALBUMINURIA; BRAIN ISCHEMIA; BRAIN NERVE CELL; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; MICROALBUMINURIA; NEPHRON; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; URINARY EXCRETION;

BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; NEPHRONS; NEURONS; RENAL INSUFFICIENCY, CHRONIC; RISK; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 79951652425     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.204     Document Type: Review

References (59)

1. Weening JJ, Remuzzi G. Exciting times for renal medicine. Lancet 375, 1227-1228 (2010).
2. Brosius FC, Hostetter TH, Kelepouris E et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease - a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the councils on high blood pressure research, cardiovascular disease in the young, and epidemiology and prevention; and the quality of care and outcomes research interdisciplinary working group. Circulation 114, 1083-1087 (2006). (Pubitemid 44358886)
3. Kirby T. Screening for chronic kidney disease shows promise. Lancet 375, 1240-1241 (2010).
4. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 375, 1296-1309 (2010).
5. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 116, 85-97 (2007). (Pubitemid 47016250)
6. Monk RD, Bennett DA. Reno-cerebrovascular disease? The incognito kidney in cognition and stroke. Neurology 67, 196-198 (2006). (Pubitemid 44305397)
7. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139, 137-147 (2003).
8. Ovbiagele B. Impairment in glomerular filtration rate or glomerular filtration barrier and occurrence of stroke. Arch. Neurol. 65, 934-938 (2008). (Pubitemid 352008478)
9. Aguilar MI, O Meara ES, Seliger S et al. Albuminuria and the risk of incident stroke and stroke types in older adults. Neurology 75, 1343-1350 (2010).
10. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Impact of microalbuminuria on incident stroke: a meta-analysis. Stroke 41, 2625-2631 (2010).
11. Ovbiagele B. Microalbuminuria: risk factor and potential therapeutic target for stroke? J. Neurol. Sci. 271, 21-28 (2008).
12. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J. Am. Soc. Nephrol. 17, 2100-2105 (2006). (Pubitemid 44141898)
13. Pucci L, Triscornia S, Lucchesi D et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin. Chem. 53, 480-488 (2007). (Pubitemid 46447945)
14. Coll E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis. 36, 29-34 (2000). (Pubitemid 30432560)
15. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am. J. Kidney Dis. 37, 79-83 (2001). (Pubitemid 32055022)
16. Kurella M, Yaffe K, Shlipak MG, Wenger NK, Chertow GM. Chronic kidney disease and cognitive impairment in menopausal women. Am. J. Kidney Dis. 45, 66-76 (2005). (Pubitemid 40038046)
17. Kurella M, Chertow GM, Fried LF et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol. 16, 2127-2133 (2005). (Pubitemid 41716444)
18. Khatri M, Wright CB, Nickolas TL et al. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke 38, 3121-3126 (2007). (Pubitemid 350175724)
19. Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MM. Kidney function is related to cerebral small vessel disease. Stroke 39, 55-61 (2008).
20. Ovbiagele B, Liebeskind DS, Pineda S, Saver JL. Strong independent correlation of proteinuria with cerebral microbleeds in patients with stroke and transient ischemic attack. Arch. Neurol. 67, 45-50 (2010).
21. Price TR, Manolio TA, Kronmal RA et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 28, 1158-1164 (1997). (Pubitemid 27248888)
22. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348, 1215-1222 (2003). (Pubitemid 36359297)
23. Bernick C, Kuller L, Dulberg C et al. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology 57, 1222-1229 (2001). (Pubitemid 32947380)
24. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 28, 1932-1939 (1997). (Pubitemid 27458998)
25. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 34, 392-396 (2003). (Pubitemid 36206336)
26. Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology 67, 224-228 (2006). (Pubitemid 44305403)
27. Cheng TY, Wen SF, Astor BC, Tao XG, Samet JM, Wen CP. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. Am. J. Kidney Dis. 52, 1051-1060 (2008).
28. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: a meta-analysis. BMJ 341, c4249 (2010).
29. Ninomiya T, Perkovic V, Verdon C et al. Proteinuria and stroke: a meta-analysis of cohort studies. Am. J. Kidney Dis. 53, 417-425 (2009).
30. Lee M, Saver JL, Chang KH, Ovbiagele B. Level of albuminuria and risk of stroke: systematic review and meta-analysis. Cerebrovasc. Dis. 30, 464-469 (2010).
31. Menon V, Shlipak MG, Wang X et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann. Intern. Med. 147, 19-27 (2007). (Pubitemid 351664630)
32. Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ. Cardiovasc. Qual. Outcomes 3(6), 675-683 (2010).
33. Slowik A, Turaj W, Iskra T, Strojny J, Szczudlik A. Microalbuminuria in nondiabetic patients with acute ischemic stroke: prevalence, clinical correlates, and prognostic significance. Cerebrovasc. Dis. 14, 15-21 (2002). (Pubitemid 34827759)
34. Terao Y, Takada M, Tanabe T, Ando Y, Fukusaki M, Sumikawa K. Microalbuminuria is a prognostic predictor in aneurysmal subarachnoid hemorrhage. Intensive Care Med. 33, 1000-1006 (2007). (Pubitemid 46835410)
35. Ovbiagele B, Sanossian N, Liebeskind DS et al. Indices of kidney dysfunction and discharge outcomes in hospitalized stroke patients without known renal disease. Cerebrovasc. Dis. 28, 582-588 (2009).
36. Ovbiagele B. Chronic kidney disease and risk of death during hospitalization for stroke. J. Neurol. Sci. 301(1-2), 46-50 (2011).
37. Ani C, Ovbiagele B. Relation of baseline presence and severity of renal disease to long-term mortality in persons with known stroke. J. Neurol. Sci. 288, 123-128 (2010).
38. Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J. Am. Soc. Nephrol. 18, 2766-2772 (2007). (Pubitemid 47531204)
39. Guyton AC, Coleman TG, Wilcox CS. Quantitative analysis of the pathophysiology of hypertension. J. Am. Soc. Nephrol. 10, 2248-2249 (1999).
40. Locatelli F, Bommer J, London GM et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol. Dial. Transplant. 16, 459-468 (2001). (Pubitemid 32229274)
41. Bikkina M, Levy D, Evans JC et al. Ventricular mass and risk of stroke in an elderly cohort - the Framingham Heart-Study. JAMA 272, 33-36 (1994). (Pubitemid 24195443)
42. Endemann DH, Schiffrin EL. Endothelial dysfunction. J. Am. Soc. Nephrol. 15, 1983-1992 (2004). (Pubitemid 39031337)
43. Stehouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J. Am. Soc. Nephrol. 17, 2106-2111 (2006). (Pubitemid 44141899)
44. Thomas GN, Lin JW, Lam WW et al. Middle cerebral artery stenosis in Type II diabetic Chinese patients is associated with conventional risk factors but not with polymorphisms of the renin-angiotensin system genes. Cerebrovasc. Dis. 16, 217-223 (2003). (Pubitemid 36928612)
45. Thomas GN, Chen XY, Lin JW et al. Middle cerebral artery stenosis increased the risk of vascular disease mortality among Type 2 diabetic patients. Cerebrovasc. Dis. 25, 261-267 (2008). (Pubitemid 351450430)
46. Furtner M, Kiechl S, Mair A et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur. Heart J. 26, 279-287 (2005). (Pubitemid 40222366)
47. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 62, 1524-1538 (2002). (Pubitemid 35286260)
48. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int. 63, 179-185 (2003). (Pubitemid 35463919)
49. Touyz RM, Mercure C, He Y et al. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension 45, 530-537 (2005). (Pubitemid 40411255)
50. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94, 437-444 (1994). (Pubitemid 24218123)
51. O Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 46, 200-204 (2005). (Pubitemid 40946514)
52. Seliger SL, Longstreth WT Jr. Lessons about brain vascular disease from another pulsating organ, the kidney. Stroke 39, 5-6 (2008).
53. Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45, 198-202 (2005). (Pubitemid 40179960)
54. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106, 672-678 (2002). (Pubitemid 34851925)
55. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 351, 1941-1951 (2004). (Pubitemid 39447135)
56. Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110, 2809-2816 (2004). (Pubitemid 39473602)
57. van de Wal RM, Gansevoort RT, van der Harst P et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension 48, 870-876 (2006). (Pubitemid 44610999)
58. Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in Type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419-430 (2010).
59. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008). (Pubitemid 351831356)